Burkitt Lymphoma Treatment Programme in Tanzania
BL is endemic to Equatorial Africa where it is the most common cancer in children aged between 5- 9 years (25%-50% of all paediatric cancers). There were an estimated 5400 new cases in Africa in 2002. INCTR is committed to reducing deaths from BL by 30% in 5 years in its treatment centres in Africa.
January 2011 - December 2013
The INCTR Challenge Fund
BL is easily curable if detected early enough. In developed countries, about 90% of treated BL patients go into remission at induction and 80% are cured. In Africa, the lack of health resources and the cost of treatment are major barriers preventing parents from seeking medical help. Chemotherapy is not enough. Overcrowded wards lead to the spread of infection. The ORCI currently has 45 children sharing 17 beds. Young children die if left untreated and unprotected from contagious diseases.
INCTR already enjoys good working links with the Ocean Road Cancer Institute (ORCI), in Dar-Es-Salaam, Tanzania. INCTR will sponsor experienced doctors to travel to ORCI to provide training and mentorship at ward level. INCTR will also use donations to purchase chemotherapy and antimicrobial drugs for use in treating BL. Annual meetings are held to review each year’s treatment programme and clinical outcomes.
Treat children with Burkitt Lymphoma.
Activities» by providing free chemotherapy drug for each child suffering from BL
The number of treated children increased. Survival rates at 12 months and 24 months increased
Enhance the quality of treatment and supportive care children patients and their parents receive.
Activities» by providing trainings to local doctors and nurses in all possible means.
Number of death from cancer decreased. Terminally ill cancer patient received pain relief treatment.
Reduce infection rate among patients.
Activities» by providing free anti-bacterial drugs for each child patient.
Less infection case. Number of death from contagious diseases decreased.
Training and mentorship of local doctors and nurses will raise professional standards within treatment centres. Treatment centres will be able to implement better treatment and supportive care protocols. Improved survival rate will encourage earlier referral by general physicians and also help the Tanzanian government make better provision for cancer control. Annual outcomes will be measured against established baseline data.
Risk Rise in price of treatment/ antimicrobial drugs
Response Use reliable suppliers of quality controlled generic drugs
Risk Shortage of expert volunteers to work in Africa
Response Extend recruitment through INCTR Partnership programme and UK International Health Links Funding Scheme
Risk Failure to deliver treatment protocols properly
Response Monitor annual outcome data
An Annual Report will be posted online on the charity’s website: http://www.challengefund.org. Data will be reported at conferences and through published journal articles.
Budget - Project Cost: £75,000Loading graph....
Amount Heading Description £45,000 Drugs Chemotherapy and anti-bacterials drugs for 100 patients / year for 3 years (approx £150 each). £15,000 Expert visit A team of radiologist, surgeon, pathologist, nurse, palliative care worker visit yearly for 3 years £15,000 Training Training couses (materials, facilities etc) once a year for 3 years
Current Funding / Pledges
Source Amount Christopher Niblett Memorial Fund £7,993 Guaranteed
Tanzania is in the bottom 10% of the world's economies in terms of per capita income and has an a average Life Expectancy of 52.5 years. The economy depends heavily on agriculture, which provides 85% of exports, and employs 80% of the workforce but topography and climatic conditions limit cultivated crops to about 4% of the land area. The Ocean Road Cancer Institute in Dar-Es-Salaam is Tanzania’s only specialised cancer hospital, serving a national population of nearly 42 million people
Children in Tanzania with Burkitt Lymphoma
The INCTR Is the leading frontline NGO fighting cancer in developing countries. Supporting INCTR programmes is the primary function of the INCTR Challenge Fund. INCTR’s African Burkitt Lymphoma Programme has been a beneficiary of the INCTR Challenge Fund since early 2008.
Read more about the Charity running this project.
Dr Trish Scanlan
the sponsored paediatric oncologist bases in ORCI. She returned to ORCI from Ireland in July 2007 and continues to be in charge of chemotherapy
Dr Twalib Ngoma
(Immediate Past President of the African Organisation for Research and Training in Cancer) is both Director of ORCI and of the INCTR Tanzanian Branch
Ms. Melissa Adde
(INCTR Director of Clinical Studies) oversees the BL Treatment programmes in Africa
Mr. Mark Lodge
(Director INCTR Challenge Fund) is responsible to the Trustees of the INCTR Challenge Fund and for oversight of the charity’s expenditure on BL